These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

116 related articles for article (PubMed ID: 36113265)

  • 21. PHYOX2: a pivotal randomized study of nedosiran in primary hyperoxaluria type 1 or 2.
    Baum MA; Langman C; Cochat P; Lieske JC; Moochhala SH; Hamamoto S; Satoh H; Mourani C; Ariceta G; Torres A; Wolley M; Belostotsky V; Forbes TA; Groothoff J; Hayes W; Tönshoff B; Takayama T; Rosskamp R; Russell K; Zhou J; Amrite A; Hoppe B;
    Kidney Int; 2023 Jan; 103(1):207-217. PubMed ID: 36007597
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Stiripentol fails to lower plasma oxalate in a dialysis-dependent PH1 patient.
    Kempf C; Pfau A; Holle J; Müller-Schlüter K; Bufler P; Knauf F; Müller D
    Pediatr Nephrol; 2020 Sep; 35(9):1787-1789. PubMed ID: 32418144
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Therapeutic RNA interference: A novel approach to the treatment of primary hyperoxaluria.
    Forbes TA; Brown BD; Lai C
    Br J Clin Pharmacol; 2022 Jun; 88(6):2525-2538. PubMed ID: 34022071
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Knockdown of lactate dehydrogenase by adeno-associated virus-delivered CRISPR/Cas9 system alleviates primary hyperoxaluria type 1.
    Zheng R; Fang X; Chen X; Huang Y; Xu G; He L; Li Y; Niu X; Yang L; Wang L; Li D; Geng H
    Clin Transl Med; 2020 Dec; 10(8):e261. PubMed ID: 33377632
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Enteric oxalate elimination is induced and oxalate is normalized in a mouse model of primary hyperoxaluria following intestinal colonization with Oxalobacter.
    Hatch M; Gjymishka A; Salido EC; Allison MJ; Freel RW
    Am J Physiol Gastrointest Liver Physiol; 2011 Mar; 300(3):G461-9. PubMed ID: 21163900
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Dual Glycolate Oxidase/Lactate Dehydrogenase A Inhibitors for Primary Hyperoxaluria.
    Ding J; Gumpena R; Boily MO; Caron A; Chong O; Cox JH; Dumais V; Gaudreault S; Graff AH; King A; Knight J; Oballa R; Surendradoss J; Tang T; Wu J; Lowther WT; Powell DA
    ACS Med Chem Lett; 2021 Jul; 12(7):1116-1123. PubMed ID: 34267881
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Still diagnosed too late and under-recognized? The first comprehensive report on primary hyperoxaluria in Poland.
    Sikora P; Zaniew M; Grenda R; Jobs K; Rubik J; Zawadzki J; Myślak M; Durlik M; Erger F; Bieniaś B; Hoppe B; Beck BB
    Pol Arch Intern Med; 2020 Dec; 130(12):1053-1063. PubMed ID: 33274618
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Safety, pharmacodynamics, and exposure-response modeling results from a first-in-human phase 1 study of nedosiran (PHYOX1) in primary hyperoxaluria.
    Hoppe B; Koch A; Cochat P; Garrelfs SF; Baum MA; Groothoff JW; Lipkin G; Coenen M; Schalk G; Amrite A; McDougall D; Barrios K; Langman CB
    Kidney Int; 2022 Mar; 101(3):626-634. PubMed ID: 34481803
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Generation of induced pluripotent stem cells-derived hepatocyte-like cells for ex vivo gene therapy of primary hyperoxaluria type 1.
    Estève J; Blouin JM; Lalanne M; Azzi-Martin L; Dubus P; Bidet A; Harambat J; Llanas B; Moranvillier I; Bedel A; Moreau-Gaudry F; Richard E
    Stem Cell Res; 2019 Jul; 38():101467. PubMed ID: 31151050
    [TBL] [Abstract][Full Text] [Related]  

  • 30. A test of the hypothesis that oxalate secretion produces proximal tubule crystallization in primary hyperoxaluria type I.
    Worcester EM; Evan AP; Coe FL; Lingeman JE; Krambeck A; Sommers A; Phillips CL; Milliner D
    Am J Physiol Renal Physiol; 2013 Dec; 305(11):F1574-84. PubMed ID: 24089413
    [TBL] [Abstract][Full Text] [Related]  

  • 31. An Investigational RNAi Therapeutic Targeting Glycolate Oxidase Reduces Oxalate Production in Models of Primary Hyperoxaluria.
    Liebow A; Li X; Racie T; Hettinger J; Bettencourt BR; Najafian N; Haslett P; Fitzgerald K; Holmes RP; Erbe D; Querbes W; Knight J
    J Am Soc Nephrol; 2017 Feb; 28(2):494-503. PubMed ID: 27432743
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Development and Validation of a New Gas Chromatography-Tandem Mass Spectrometry Method for the Measurement of Enrichment of Glyoxylate Metabolism Analytes in Hyperoxaluria Patients Using a Stable Isotope Procedure.
    van Harskamp D; Garrelfs SF; Oosterveld MJS; Groothoff JW; van Goudoever JB; Schierbeek H
    Anal Chem; 2020 Jan; 92(2):1826-1832. PubMed ID: 31867958
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Systemic Alanine Glyoxylate Aminotransferase mRNA Improves Glyoxylate Metabolism in a Mouse Model of Primary Hyperoxaluria Type 1.
    Kukreja A; Lasaro M; Cobaugh C; Forbes C; Tang JP; Gao X; Martin-Higueras C; Pey AL; Salido E; Sobolov S; Subramanian RR
    Nucleic Acid Ther; 2019 Apr; 29(2):104-113. PubMed ID: 30676254
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Targeting kidney inflammation as a new therapy for primary hyperoxaluria?
    Martin-Higueras C; Ludwig-Portugall I; Hoppe B; Kurts C
    Nephrol Dial Transplant; 2019 Jun; 34(6):908-914. PubMed ID: 30169827
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Oxalate dynamics in chronic renal failure. Comparison with normal subjects and patients with primary hyperoxaluria.
    Morgan SH; Purkiss P; Watts RW; Mansell MA
    Nephron; 1987; 46(3):253-7. PubMed ID: 3306417
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Primary hyperoxaluria type III gene HOGA1 (formerly DHDPSL) as a possible risk factor for idiopathic calcium oxalate urolithiasis.
    Monico CG; Rossetti S; Belostotsky R; Cogal AG; Herges RM; Seide BM; Olson JB; Bergstrahl EJ; Williams HJ; Haley WE; Frishberg Y; Milliner DS
    Clin J Am Soc Nephrol; 2011 Sep; 6(9):2289-95. PubMed ID: 21896830
    [TBL] [Abstract][Full Text] [Related]  

  • 37. A report from the European Hyperoxaluria Consortium (OxalEurope) Registry on a large cohort of patients with primary hyperoxaluria type 3.
    Martin-Higueras C; Garrelfs SF; Groothoff JW; Jacob DE; Moochhala SH; Bacchetta J; Acquaviva C; Zaniew M; Sikora P; Beck BB; Hoppe B
    Kidney Int; 2021 Sep; 100(3):621-635. PubMed ID: 33865885
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Plasma oxalate levels in primary hyperoxaluria type I show significant intra-individual variation and do not correlate with kidney function.
    Hillebrand P; Hoppe B
    Pediatr Nephrol; 2020 Jul; 35(7):1227-1233. PubMed ID: 32274573
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Improving Treatment Options for Primary Hyperoxaluria.
    Hoppe B; Martin-Higueras C
    Drugs; 2022 Jul; 82(10):1077-1094. PubMed ID: 35779234
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Effects of alanine:glyoxylate aminotransferase variants and pyridoxine sensitivity on oxalate metabolism in a cell-based cytotoxicity assay.
    Fargue S; Knight J; Holmes RP; Rumsby G; Danpure CJ
    Biochim Biophys Acta; 2016 Jun; 1862(6):1055-62. PubMed ID: 26854734
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 6.